Specifically, they call for a shift in emphasis in drug development towards understanding how people differ in their response to pain medications to develop more precise, safer, and less addictive treatments. “Pain is a syndrome that is poorly understood and research on pain is poorly resourced relative to its preva¬lence and cost, especially in terms of shattered lives and lost productivity,” writes Tilo Grosser, MD, an associate professor of Pharmacology, and Garret A. FitzGerald, MD, FRS, director of the Institute for Translational Medicine and Therapeutics at Penn, along with Clifford J. Woolf, from the Boston Children’s Hospital and Harvard Medical School. This plan is especially urgent given no analgesic drugs directed at novel targets have been approved in the past five years.
The authors reason that the opioid epidemic has attained the scale of the HIV/AIDS epidemic at its peak in the mid-1990s, and that a massive and diversified effort by multiple stakeholders is necessary to address the rash of painkiller overdoses: “Encouragingly, this broad-based strategy worked, converting the inevitable lethality of AIDS to a reasonably well controlled, chronic disease.”
They propose a bold plan for how to pay for this new research: A substantial investment by the pharmaceutical industry and government to form a public-private partnership to create a $10 billion research fund administered by the National Institutes of Health to complement the $1 billion allocated for combating the opioid epidemic in the 21st Century Cures Act.
They identify interventions in three areas: a better understanding of pain physiology, drug development, and individual variability in response to pain. First, new investigations could address ways to manipulate thresholds of pain and distort pain percep¬tion, the difference between inflammatory pain and neuropathic pain, the heritability of pain perception, and the transition from acute to chronic pain. They also cite sex and aging as influences on the perception of pain and the relationship between sleep and pain as areas ripe for research.
With regard to developing new medications, emerging drug targets to control pain include many types of ion channels that transverse cell membranes, cell-surface receptors, and inflammatory molecules. They also mention a need to understand the pla¬cebo response as well as such complementary approaches to pain management as acupuncture, yoga, cognitive behavioral and mindfulness techniques, and meditation.The authors assert that to gain insight into the individual response to pain, researchers need to identify biomarkers to measure drug efficacy, the risk of adverse effects, and to inform the design of clinical trials. “For example, crowdsourc¬ing approaches or electronic health records linked to biobanks can be used to character¬ize the frequency of the diverse subpheno¬types of pains,” they wrote.
Penn Medicine is one of the world's leading academic medical centers, dedicated to the related missions of medical education, biomedical research, and excellence in patient care. Penn Medicine consists of the Raymond and Ruth Perelman School of Medicine at the University of Pennsylvania (founded in 1765 as the nation's first medical school) and the University of Pennsylvania Health System, which together form a $5.3 billion enterprise.
The Perelman School of Medicine has been ranked among the top five medical schools in the United States for the past 18 years, according to U.S. News & World Report's survey of research-oriented medical schools. The School is consistently among the nation's top recipients of funding from the National Institutes of Health, with $373 million awarded in the 2015 fiscal year.
The University of Pennsylvania Health System's patient care facilities include: The Hospital of the University of Pennsylvania and Penn Presbyterian Medical Center -- which are recognized as one of the nation's top "Honor Roll" hospitals by U.S. News & World Report -- Chester County Hospital; Lancaster General Health; Penn Wissahickon Hospice; and Pennsylvania Hospital -- the nation's first hospital, founded in 1751. Additional affiliated inpatient care facilities and services throughout the Philadelphia region include Chestnut Hill Hospital and Good Shepherd Penn Partners, a partnership between Good Shepherd Rehabilitation Network and Penn Medicine.
Penn Medicine is committed to improving lives and health through a variety of community-based programs and activities. In fiscal year 2015, Penn Medicine provided $253.3 million to benefit our community.
RSS